Zydus Lifesciences Typhoid Vaccine Secures WHO Prequalification Status
Zydus Lifesciences has made significant strides in public health with its Typhoid vaccine, ZyVac TCV, which has recently received WHO prequalification. This acceptance from the World Health Organization paves the way for its purchase by UN agencies, reinforcing the company's commitment to fighting Salmonella typhi infections globally.
Manufactured at Zydus Biotech Park in Ahmedabad, ZyVac TCV is indicated for active immunization against typhoid fever in individuals aged between 6 months and 65 years. With over 150 million doses procured annually by UN agencies, the vaccine's adoption is essential for controlling this infectious disease in prevalent regions, particularly in India, Africa, and Southeast Asia.
In India, where the country accounts for a staggering 75 percent of typhoid incidence and mortality in South Asia, the introduction of ZyVac TCV is expected to make a significant impact.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.